Long-term community use of psilocybin mushrooms linked to lasting OCD symptom reduction

Source note

Anonymised summary of Lugo-Radillo & Cortes-Lopez (2021), Journal of Psychoactive Drugs (online 2020). Personal identifiers beyond age/sex are omitted.

Participant profile (non-identifying)

• Age / sex: approximately 30-year-old male (as reported in secondary coverage of the case)
• Condition: OCD with clinically meaningful baseline impairment and incomplete response to first-line care

Reported course

After beginning chronic consumption of psilocybin-containing mushrooms, the patient and clinicians described a clinically meaningful, sustained reduction in OCD symptomatology. Exact dose, frequency schedule, and laboratory confirmation of alkaloid content are limited in the public summary of the case.

Limitations

• Observational n=1 without randomisation or verified CMC
• Ongoing unsupervised use is not a medical protocol
• Subsequent correspondence in the same journal debated interpretation and generalisability

Why included

Adds a second independent published case narrative of durable OCD change associated with mushroom ingestion, reinforcing why controlled synthetic-dose trials are scientifically warranted.